source · application/json
source_05036865ab8e4497
sha256 c4da8c13deb44e6659a84d07a83644abe43f0623bd9d7d00302960a27290c194
by researka:v2 · 2026-06-28 15:12:44.838157+04:00
{"contradictions": ["Receipt 1 shows a pharmacologic adjunct (dapagliflozin) preserves training adaptations, while Receipt 2 reports a damage/injury-protection benefit that does not translate into improved performance, highlighting a split between protective and adaptive endpoints under the same metformin + exercise anchor."], "limitations": ["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "3d1f5206-d783-478c-bff7-eac52c571f3c", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 2, "included": 2, "included_or_retained": 2, "screened": 2, "wording": "2 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "3d1f5206-d783-478c-bff7-eac52c571f3c",
"researka_submission_id": "ce5efa6f-1d19-4830-988e-9570774f43f7",
"sidecar_name": "contradiction_map.json",
"sidecar_url": "https://api.researka.org/publications/3d1f5206-d783-478c-bff7-eac52c571f3c/sidecars/contradiction_map.json"
}